Literature DB >> 9805839

Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis.

C N Paramasivan1, G Kubendiran, D Herbert.   

Abstract

To study the activity of metronidazole on persisting tubercle bacilli, BALB/c mice were infected with Mycobacterium tuberculosis and, after 14 days, treated with isoniazid (H) or rifampicin (R) or isoniazid + rifampicin (HR) for 2 months. An untreated group and a group treated with metronidazole (M) alone served as controls. At the end of 2 months, M was added to the H, R, and HR regimen in half the mice, and the treatment was continued for 1 more month in all mice. At the end of treatment, no viable organisms were detected in the lung or spleen of mice treated with HR or HRM regimens. In contrast, compared to the mice treated with R alone, the log10 colony forming units (cfu) of mice treated with RM were lower by 1.84 and 0.52 in the lung and spleen, respectively. Similarly, compared to the H group, the log10 cfu were lower by 0.67 in the spleen of mice treated with HM, and no additional effect due to M was seen in the lung. Three months after stopping treatment, viable organisms were isolated from both the organs of all the groups. However, the log10 cfu in the lung and spleen for the groups with metronidazole were below the log10 cfu for the respective single or 2 drug groups, except the log10 cfu in the lung for the RM group. These findings suggest that metronidazole, given with bactericidal drugs such as rifampicin and isoniazid may be of value in eliminating persisting tubercle bacilli, but further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9805839

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  8 in total

Review 1.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

2.  Oxygen depletion-induced dormancy in Mycobacterium bovis BCG.

Authors:  A Lim; M Eleuterio; B Hutter; B Murugasu-Oei; T Dick
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

3.  Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.

Authors:  Elisabetta Iona; Federico Giannoni; Manuela Pardini; Lara Brunori; Graziella Orefici; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

Review 4.  New drugs and regimens for treatment of TB.

Authors:  Eric Leibert; William N Rom
Journal:  Expert Rev Anti Infect Ther       Date:  2010-07       Impact factor: 5.091

Review 5.  Nitroimidazoles for the treatment of TB: past, present and future.

Authors:  Tathagata Mukherjee; Helena Boshoff
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 6.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

7.  Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates.

Authors:  Laura E Via; P Ling Lin; Sonja M Ray; Jose Carrillo; Shannon Sedberry Allen; Seok Yong Eum; Kimberly Taylor; Edwin Klein; Ujjini Manjunatha; Jacqueline Gonzales; Eun Gae Lee; Seung Kyu Park; James A Raleigh; Sang Nae Cho; David N McMurray; JoAnne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

8.  Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Donald R Hoff; Megan L Caraway; Elizabeth J Brooks; Emily R Driver; Gavin J Ryan; Charles A Peloquin; Ian M Orme; Randall J Basaraba; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.